September 13, 2018, 2:00 PM ET: The How and Why of Deprescribing
- Nicole Brandt, PharmD, MBA, BCGP, BCPP, FASCP, Executive Director, Peter Lamy Center on Drug Therapy and Aging; Professor, University of Maryland School of Pharmacy
Florian Daragjati, PharmD, BCPS, Director, Ascension Center of Excellence for Antimicrobial Stewardship and Infection Prevention
Lynn Deguzman, PharmD, BCGP, Regional Clinical Operations Manager, Kaiser Permanente
- Leslie J. Pelton, MPA, Director, Institute for Healthcare Improvement
Leanne Phillips, PharmD, BCPS, Clinical Pharmacy Coordinator, St. Vincent’s East, Ascension
The ground is shifting for prescription medication in the US and Canada, and in other countries, too. There’s much talk and publicity about weaning people off drugs, or what is referred to as “deprescribing”: a process that entails taking patients off some of their medications or tapering down the dosages.
The underlying reasons for deprescribing include concerns about polypharmacy, especially the impact on older and frail adults; antibiotic resistance caused by inappropriate and excessive use; and the ongoing opioid epidemic connected to years of overprescribing highly addictive medicines for pain.
A growing number of health care organizations are working on how to safely implement deprescribing. On the September 13 WIHI: The Why and How of Deprescribing, learn from the experiences of two such organizations – Kaiser Permanente (KP) and Ascension.
innovative work on deprescribing led by the Bruyère Research Institute in Ottawa, Canada, both Ascension and KP have been part of a larger IHI collaborative on deprescribing this past year and a half — testing and adapting the best practices in their systems.
At Ascension, one hospital is focusing on deprescribing (or, whenever possible, not introducing) opioids and sedatives among a targeted group of patients; three other hospitals are zeroed in on deprescribing proton pump inhibitors for gastrointestinal problems because of potential harm caused by long-term use.
In KP’s Northern California region, deprescribing is focused on adults over the age of 75 who are taking medication for type 2 diabetes or high blood pressure, to help reduce the risks for hypoglycemia and hypotension at a more advanced age.
The WIHI panel also includes Nicole Brandt, lead faculty for the IHI deprescribing collaborative of 13 organizations that includes KP and Ascension. All the panelists are eager to share what they’ve learned to hopefully inspire others in health care to start their own deprescribing initiatives. We hope you’ll join us!
Please click here to create a calendar invite for the 2 PM ET broadcast.